newdrugapprovals.org
Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV
delafloxacin Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Rib-X Pharmaceuticals, Inc. has initiated a Phase 3 clinical trial of a Captisol-enabled™ int…